Christopher Hulton, PhD

Research Scientist at C4 Therapeutic, Watertown, Massachusetts

Christopher Hulton, PhD

Research Scientist at C4 Therapeutic, Watertown, Massachusetts

Share
Print
Share
Print
Pictured: Christopher Hulton

Dissertation

Direct Genome Editing of Patient-Derived Xenografts Using CRISPR-Cas9 Enables Rapid in vivo Functional Genomics (2019)

Mentor

Charles M. Rudin

End Year

2019

Education

BS, Northeastern University

Current Title & Affiliations

Research Scientist, C4 Theraputics Inc.

Publications

Wohlhieter CA, Richards AL, Uddin F, Hulton CH, Quintanal-Villalonga À, Martin A, de Stanchina E, Bhanot U, Asher M, Shah NS, Hayatt O, Buonocore DJ, Rekhtman N, Shen R, Arbour KC, Donoghue M, Poirier JT, Sen T, Rudin CM. (2020) Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. Cell Rep.

Hulton, C.H., Costa, E.A., Shah, N.S. et al. Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics. (2020) Nat Cancer 1, 359–369 (2020). doi.org/10.1038/s43018-020-0040-8